An alternative to EpiPen is about to return to the marketplace, but with a complicated pricing strategy that may appeal to some consumers, but not necessarily to insurers.
Starting next month, Kaleo will begin selling its Auvi-Q allergic-reaction device for $360 in cash to people without insurance. But the company will cover the cost entirely for those with high-deductible insurance plans or who have a household income less than $100,000 and also lack insurance.
About the Author Reprints
